Detrimental eeffect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages

  Cicconi, Paola ^a   Bini, Teresa ^a   Barassi, Alessandra ^b   Casana, Maddalena ^a   Turri, Olivia ^c   Pateri, Francesca ^b   Marchetti, Giulia C ^a   Biondi, Maria Luisa ^c   D'Eril, Gianlodovico Melzi ^b   Manforte, Antonella D'Arminio ^a  

^a Department of Medicine Surgery and Dentistry   (Italy)

^b Biochemistry Laboratory   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ADULT; BILIRUBIN BLOOD LEVEL; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; FEMALE; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BLOOD; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PLASMA;

ADULT; ANTI-HIV AGENTS; BILIRUBIN; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PLASMA; POLYMORPHISM, GENETIC; PYRIDINES;

EID: 79951801978     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318203e7e7     Document Type: Letter

References (9)

1. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucoronosyltransferase halotype. Hepatology. 2006;44:1324-1332. (Pubitemid 44748383)
2. Strassburg CP, Lankisch TO, Manns MP, et al. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol. 2008;82:415-433.
3. Rodríguez-Nòvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21: 41-46.
4. Cleijsen RM, Van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007;60:897-900. (Pubitemid 47434275)
5. Guaraldi G, Cocchi S, Motta A, et al. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother. 2008;62: 1356-1364.
6. Nauck M, Stein U, Von Karger S, et al. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem. 2000;46: 1995-1997.
7. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection. 2009;37:244-249.
8. Girard H, Thibaudeau J, Court MH, et al. UGT1A1 polymorfisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology. 2005;42:448-457. (Pubitemid 41061098)
9. Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs. 2005;23:539-545. (Pubitemid 43162473)